Analysis Of Income And Expense [Abstract]

Innate Pharma - Filing #2811003

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue from sale of goods	—	11,000 EUR	—	—	—	—	—	—	—	—	59,000 EUR	—	—	—	—	—
Revenue	—	61 641 EUR	—	—	—	—	—	—	—	—	57 674 EUR	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	56 022 EUR	—	—	—	—	—	—	—	—	51 663 EUR	—	—	—	—	—
Finance income (cost)	—	5 099 EUR	—	—	—	—	—	—	—	—	546,000 EUR	—	—	—	—	—
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	18 288 EUR	—	—	—	—	—	—	—	—	22 436 EUR	—	—	—	—	—
Operating expense	—	74 310 EUR	—	—	—	—	—	—	—	—	74 099 EUR	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	— EUR	276,000 EUR	718,000 EUR	— EUR	994,000 EUR	— EUR	— EUR	— EUR	— EUR	428,000 EUR	428,000 EUR	— EUR	—	— EUR	— EUR	— EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	— EUR	6 900 EUR	324,000 EUR	7 570 EUR	994,000 EUR	— EUR	— EUR	— EUR	— EUR	362,000 EUR	57 741 EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR